Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Probiotics have been investigated for their potential role in supporting liver health, including in hepatitis, due to their ability to modulate gut microbiota and reduce systemic inflammation. Research suggests that gut-liver axis disturbances contribute to the progression of liver diseases, including various forms of hepatitis. Some clinical trials and preclinical studies have found that specific probiotic strains (such as Lactobacillus and Bifidobacterium) may help improve liver function tests, reduce liver inflammation, and decrease markers of oxidative stress in patients with hepatitis B or C. The hypothesized mechanisms include restoration of gut barrier integrity, reduction of endotoxin translocation, and modulation of immune responses.

However, the evidence is still emerging and not robust. Most studies are small, of short duration, and often use different probiotic strains, making it difficult to draw firm conclusions or establish standardized recommendations. There is insufficient high-quality, large-scale clinical trial data to support the routine use of probiotics for hepatitis treatment. Major liver and infectious disease guidelines do not currently recommend probiotics as a primary or adjunctive therapy for hepatitis. While the scientific rationale exists and preliminary findings are promising, more research is needed to determine efficacy, optimal strains, dosages, and patient selection.

More about Probiotic (unspecified)
More about Hepatitis

Other ingredients used for Hepatitis

Other health conditions supported by Probiotic (unspecified)

Products containing Probiotic (unspecified)